The manufacturer of pharmaceutical packaging and systems is benefiting greatly from the sharp rise in sales of diabetes and weight loss products. CEO Siemssen expects further growth from the increasing spread of particularly sensitive biotech active ingredients.
(Photo: Gerresheimer AG)
Dusseldorf, Frankfurt Almost 60 percent price growth this year alone, a doubling since September – the Düsseldorf Gerresheimer AG share is currently one of the best performers on the Frankfurt Stock Exchange. Investors are expecting great things from the company, which makes pharmaceutical packaging and drug delivery systems.
Gerresheimer boss Dietmar Siemssen wants to deliver. Sales are expected to almost double in the medium term, with margins rising at the same time, he says in an interview with the Handelsblatt: “The most exciting and best years for Gerresheimer are yet to come.” Ironically, the medical fight against obesity should help the MDax group to gain more weight .
Drugs for the metabolic disease diabetes and adiposity (obesity) are a new billion-dollar market for the pharmaceutical industry. The run on funds is huge. In the celebrity world, the diabetes drug Ozempic from the Danish company Novo Nordisk has recently caused a stir – as a weight loss injection.
Weight loss injection: Huge sales potential through diabetes drugs
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Further
Read on now
Get access to this and every other article in the
web and in our app.
Further